Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
119M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
48.2M
-
Shares change
-
+1.94M
-
Total reported value, excl. options
-
$927M
-
Value change
-
+$37.2M
-
Put/Call ratio
-
0.13
-
Number of buys
-
50
-
Number of sells
-
-33
-
Price
-
$19.26
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) as of Q1 2022
117 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
Arcutis Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (ARQT) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.2M shares
of 119M outstanding shares and own 40.4% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (8.43M shares), FMR LLC (7.56M shares), ORBIMED ADVISORS LLC (6.07M shares), BlackRock Inc. (4.32M shares), Bain Capital Life Sciences Investors, LLC (3.98M shares), Polar Capital Holdings Plc (1.78M shares), Point72 Asset Management, L.P. (1.7M shares), VANGUARD GROUP INC (1.53M shares), Logos Global Management LP (1.5M shares), and STATE STREET CORP (1.19M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.